Last year, shares of molecular diagnostics company Exact Sciences (NASDAQ: EXAS) dropped by about 40%. However, 2023 is proving to be very different, at least so far. Exact Sciences is up by 32% since the year started. There is no question that's an impressive performance, but it hardly constitutes a reason to invest.

Short-term gains are great, but can the company deliver market-beating returns over the long run? In my view, the answer is a resounding yes. Let's consider why it's worth buying shares of Exact Sciences today.

Continue reading

Source Fool.com